Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00146211
Status:
COMPLETED
Last Update Posted:
2007-12-27
First Post:
2005-09-02
Brief Title:
TREND-HD - A Trial of Ethyl-EPA Miraxion in Treating Mild to Moderate Huntingtons Disease
Sponsor:
Amarin Neuroscience Ltd
Organization:
Amarin Neuroscience Ltd
Study Overview
Official Title:
A Multicenter Double Blind Randomized Parallel Group Placebo-Controlled Trial of Ethyl-EPA Miraxion in Subjects With Mild to Moderate Huntingtons Disease
Status:
COMPLETED
Status Verified Date:
2007-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed to determine the effect of 2 gramday of ethyl-EPA on motor movement signs and symptoms of Huntington disease
Detailed Description:
Multi-center double blind placebo-controlled study with parallel groups of outpatients with early symptomatic Huntingtons disease Participants will be randomized to receive 1 gram twice daily 2 gramday total daily dose of active study drug or placebo The 6-month placebo-controlled phased will be followed by a subsequent 6-month open-label extension phase with all subjects receiving 1 gram twice daily 2 gramsday total daily dose of active study drug
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None